Search

Shuwen He

from Edgewater, NJ
Age ~41
Get Report
Also known as:
He Shuwen
Related to:
Doris K Lau, 87
Connected to:
Ai L He, 46Alina He, 37Angel M He, 34Anli He, 47Benjamin B He, 51Brian He, 32Candice J He, 33Charles C He, 62Chuan He, 51Chunxiang He, 47

Shuwen He Phones & Addresses

  • Edgewater, NJ
  • West New York, NJ
  • New Milford, NJ
  • Newport, NJ
  • Philadelphia, PA
  • Flushing, NY

Resumes

Resumes

Shuwen He Photo 1

Senior Associate, Budget Management & Talent Operations At Eisai

View page
Position:
Senior Associate, Budget Management & Talent Operations at Eisai
Location:
Greater New York City Area
Industry:
Pharmaceuticals
Work:
Eisai - Woodcliff Lake, NJ since Jun 2012
Senior Associate, Budget Management & Talent Operations
Eisai Inc. - Woodcliff Lake Nov 2011 - Jun 2012
Senior Communications Associate
Eisai Inc. Jan 2009 - Oct 2011
Communications Associate
Education:
University of Pennsylvania 2007 - 2008
Master of Biotechnology 慶応義塾大学 / Keio University 2003 - 2007
Bachelor of Engineering, Biosciences and Informatics
Shuwen He Photo 2

Shuwen He

View page

Publications

Us Patents

Acylated Spiropiperidine Derivatives As Melanocortin-4 Receptor Modulators

View page
US Patent:
7652024, Jan 26, 2010
Filed:
Oct 13, 2006
Appl. No.:
12/083567
Inventors:
Raman K. Bakshi - Edison NJ, US
James P. Dellureficio - Millington NJ, US
Peter H. Dobbelaar - Morris Plains NJ, US
Liangqin Guo - Edison NJ, US
Shuwen He - Edison NJ, US
Qingmei Hong - Scotch Plains NJ, US
Ravi P. Nargund - East Brunswick NJ, US
Zhixiong Ye - West Windsor NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/438
C07D 491/107
US Classification:
514278, 546 17, 544125, 5142328
Abstract:
Certain novel N-acylated spiropiperidine derivatives are ligands of the human melanocortin receptor(s) and, in particular, are selective ligands of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of MC-4R, such as obesity, diabetes, nicotine addiction, alcoholism, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.

Substituted Imidazoles As Bombesin Receptor Subtype-3 Modulators

View page
US Patent:
8183275, May 22, 2012
Filed:
Oct 16, 2007
Appl. No.:
12/311672
Inventors:
Peter H. Dobbelaar - Morris Plains NJ, US
Christopher L. Franklin - Keasbey NJ, US
Allan Goodman - Media PA, US
Cheng Guo - Schenectady NY, US
Peter R. Guzzo - Niskayuna NY, US
Mark Hadden - Albany NY, US
Shuwen He - Edison NJ, US
Alan J. Henderson - Albany NY, US
Tianying Jian - Westfield NJ, US
Linus S. Lin - Westfield NJ, US
Jian Liu - Edison NJ, US
Ravi P. Nargund - East Brunswick NJ, US
Megan Ruenz - Grayslake IL, US
Bruce J. Sargent - Delmar NY, US
Iyassu K. Sebhat - Jersey City NJ, US
Larry Yet - Albany NY, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
Albany Molecular Research, Inc. - Albany NY
International Classification:
A61K 31/4178
A61K 31/4164
C07D 471/04
C07D 401/10
C07D 403/10
C07D 233/64
US Classification:
514393, 514360, 514385, 514387, 514390, 548126, 5483001, 548416, 548578, 546113, 5462727, 544333, 544405
Abstract:
Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.

Acylated Spiropiperidine Derivatives As Melanocortin-4 Receptor Agonists

View page
US Patent:
20060183904, Aug 17, 2006
Filed:
Mar 31, 2004
Appl. No.:
10/548350
Inventors:
Liangqin Guo - Edison NJ, US
Shuwen He - Edison NJ, US
Tianying Jian - Westfield NJ, US
Jian Liu - Edison NJ, US
Yingjie Lai - Edison NJ, US
Ravi Nargund - East Brunswick NJ, US
Iyassu Sebhat - New York NY, US
Feroze Ujjainwalla - Scotch Plains IN, US
Zhixiong Ye - Princeton NJ, US
Jonathan Young - Kendall Park NJ, US
International Classification:
C07D 401/00
C07D 453/00
US Classification:
546017000
Abstract:
Certain novel N-acylated spiropiperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.

Beta Carboline Derivatives As Antidiabetic Compounds

View page
US Patent:
20100184758, Jul 22, 2010
Filed:
Jul 15, 2008
Appl. No.:
12/668822
Inventors:
Peter H. Dobbelaar - Morris Plains NJ, US
Wu Du - Monroe Township NJ, US
Liangqin Guo - Edison NJ, US
William K. Hagmann - Westfield NJ, US
Shuwen He - Edison NJ, US
Tianying Jian - Westfield NJ, US
Jian Liu - Edison NJ, US
Ravi P. Nargund - East Brunswick NJ, US
Alexander Pasternak - Princeton NJ, US
Shrenik K. Shah - Metuchen NJ, US
Quang T. Truong - Morganville NJ, US
Zhixiong Ye - Princeton NJ, US
Raman Bakshi - Edison NJ, US
International Classification:
A61K 31/5377
C07D 471/14
A61K 31/437
C07D 413/14
C07D 403/14
A61K 31/501
A61K 31/4995
A61K 31/506
A61P 3/10
A61P 3/04
A61P 3/00
A61P 3/06
A61P 9/12
US Classification:
5142328, 546 84, 514292, 544126, 544238, 51425204, 544361, 51425303, 544333, 514256, 544315, 514274
Abstract:
Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety.

Oxadiazole Beta Carboline Derivatives As Antidiabetic Compounds

View page
US Patent:
20120264777, Oct 18, 2012
Filed:
Jan 11, 2011
Appl. No.:
13/518015
Inventors:
Liangqin Guo - Edison NJ, US
William K. Hagmann - Westfield NJ, US
Shuwen He - Edison NJ, US
Zhong Lai - Scotch Plains NJ, US
Jian Liu - Edison NJ, US
Ravi P. Nargund - East Brunswick NJ, US
Shrenik K. Shah - Metuchen NJ, US
Quang T. Truong - Morganville NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/437
A61P 3/10
A61P 9/12
A61P 3/04
A61P 3/06
A61P 3/00
C07D 471/04
A61P 5/48
US Classification:
514292, 546 87
Abstract:
Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin sub-type receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety.

Ampk Activators

View page
US Patent:
20220340599, Oct 27, 2022
Filed:
Jun 22, 2022
Appl. No.:
17/846819
Inventors:
- New York NY, US
Shuwen HE - Fanwood NJ, US
International Classification:
C07D 519/00
A61P 3/10
C07D 493/04
C07F 9/6561
A61P 1/00
Abstract:
This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists, super agonists, full agonists, or partial agonists.

Gpr40 Agonists

View page
US Patent:
20220289772, Sep 15, 2022
Filed:
May 16, 2022
Appl. No.:
17/745126
Inventors:
- New York NY, US
Shuwen HE - Fanwood NJ, US
International Classification:
C07F 9/38
A61K 31/662
A61K 31/10
C07C 309/24
C07F 9/30
C07F 9/58
A61K 31/675
C07F 9/59
Abstract:
This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

Gpr40 Agonists

View page
US Patent:
20220226298, Jul 21, 2022
Filed:
May 22, 2020
Appl. No.:
17/614100
Inventors:
- New York NY, US
Shuwen HE - Fanwood NJ, US
International Classification:
A61K 31/4418
A61K 45/06
C07C 69/94
C07D 261/18
C07D 207/16
C07D 213/647
C07D 295/205
C07D 211/62
C07D 213/75
C07D 401/10
C07D 405/12
C07F 9/38
C07F 9/30
C07F 9/58
A61K 31/235
A61K 31/415
A61K 31/40
A61K 31/495
A61K 31/445
A61K 31/44
A61K 31/454
A61K 31/397
A61K 31/194
A61K 31/443
A61K 31/675
Abstract:
This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.
Control profile
Shuwen He from Edgewater, NJ, age ~41 Get Report